{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"12.9","value":"7.0"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"9.6","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"Defined as the time from the first objective response to documented disease progression or death from any cause, whichever occurred first.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Tucatinib in combination with capecitabine \\& trastuzumab","id":"OG000","title":"Tuc+Cap+Tra"},{"description":"Placebo in combination with capecitabine \\& trastuzumab","id":"OG001","title":"Pbo+Cap+Tra"}],"paramType":"MEDIAN","populationDescription":"ITT-OS Population: Includes all randomized participants evaluated by their randomized treatment assignment.","reportingStatus":"POSTED","timeFrame":"33.2 months","title":"DOR Per RECIST 1.1 as Determined by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"months"}